These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 37891392)

  • 1. Trends in Formulation Approaches for Sustained Drug Delivery to the Posterior Segment of the Eye.
    Biswas A; Choudhury AD; Bisen AC; Agrawal S; Sanap SN; Verma SK; Mishra A; Kumar S; Bhatta RS
    AAPS PharmSciTech; 2023 Oct; 24(8):217. PubMed ID: 37891392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances.
    Wang R; Gao Y; Liu A; Zhai G
    J Drug Target; 2021 Aug; 29(7):687-702. PubMed ID: 33474998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies.
    Alshaikh RA; Waeber C; Ryan KB
    Adv Drug Deliv Rev; 2022 Aug; 187():114342. PubMed ID: 35569559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review on recent drug delivery systems for posterior segment of eye.
    Nayak K; Misra M
    Biomed Pharmacother; 2018 Nov; 107():1564-1582. PubMed ID: 30257375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymers and their engineered analogues for ocular drug delivery: Enhancing therapeutic precision.
    Biswas A; Kumar S; Choudhury AD; Bisen AC; Sanap SN; Agrawal S; Mishra A; Verma SK; Kumar M; Bhatta RS
    Biopolymers; 2024 Jul; 115(4):e23578. PubMed ID: 38577865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug delivery to the posterior segment of the eye.
    Fischer N; Narayanan R; Loewenstein A; Kuppermann BD
    Eur J Ophthalmol; 2011; 21 Suppl 6():S20-6. PubMed ID: 23264325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.
    Bisht R; Jaiswal JK; Rupenthal ID
    Med Hypotheses; 2017 Jun; 103():5-9. PubMed ID: 28571808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases.
    Wu Y; Li X; Fu X; Huang X; Zhang S; Zhao N; Ma X; Saiding Q; Yang M; Tao W; Zhou X; Huang J
    Adv Sci (Weinh); 2024 Aug; 11(32):e2403399. PubMed ID: 39031809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery.
    Qi Q; Wei Y; Zhang X; Guan J; Mao S
    J Control Release; 2023 Sep; 361():191-211. PubMed ID: 37532148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of therapeutics for deep-seated ocular conditions - status quo.
    Nguyen H; Eng S; Ngo T; Dass CR
    J Pharm Pharmacol; 2018 Aug; 70(8):994-1001. PubMed ID: 29675844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent patents on ocular drug delivery systems.
    Conway BR
    Recent Pat Drug Deliv Formul; 2008; 2(1):1-8. PubMed ID: 19075892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posterior Segment Ophthalmic Drug Delivery: Role of Muco-Adhesion with a Special Focus on Chitosan.
    Burhan AM; Klahan B; Cummins W; Andrés-Guerrero V; Byrne ME; O'Reilly NJ; Chauhan A; Fitzhenry L; Hughes H
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanotechnology based drug delivery systems for the treatment of anterior segment eye diseases.
    Onugwu AL; Nwagwu CS; Onugwu OS; Echezona AC; Agbo CP; Ihim SA; Emeh P; Nnamani PO; Attama AA; Khutoryanskiy VV
    J Control Release; 2023 Feb; 354():465-488. PubMed ID: 36642250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biodegradable Polymer-Based Drug-Delivery Systems for Ocular Diseases.
    Tsung TH; Tsai YC; Lee HP; Chen YH; Lu DW
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Nanotherapies for the Posterior Segment of the Eye: An Integrative Review on Recent Advancements and Challenges.
    Gogoi NR; Marbaniang D; Pal P; Ray S; Mazumder B
    Pharm Nanotechnol; 2022 Nov; 10(4):268-278. PubMed ID: 35946098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal hydrogels for sustained release of therapeutic proteins.
    Ilochonwu BC; Urtti A; Hennink WE; Vermonden T
    J Control Release; 2020 Oct; 326():419-441. PubMed ID: 32717302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depot formulations to sustain periocular drug delivery to the posterior eye segment.
    Agban Y; Thakur SS; Mugisho OO; Rupenthal ID
    Drug Discov Today; 2019 Aug; 24(8):1458-1469. PubMed ID: 30930148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug delivery to the posterior segment of the eye.
    Thrimawithana TR; Young S; Bunt CR; Green C; Alany RG
    Drug Discov Today; 2011 Mar; 16(5-6):270-7. PubMed ID: 21167306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
    Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
    J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.